Osteoporosis piece of multi-morbidity puzzle in geriatric care

Mount Sinai Journal of Medicine

Volumn 78, Issue 4, 2011, Pages 515-526

  Colõn Emeric, Cathleen ^a   O'Connell, Mary Beth ^b   Haney, Elizabeth ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

depression; multimorbidity; osteoporosis

Indexed keywords

ANASTROZOLE; CARBAMAZEPINE; CYCLOSPORIN; DEXAMETHASONE; EXEMESTANE; FUROSEMIDE; GOSERELIN; HEPARIN; LETROZOLE; LEUPRORELIN; LEVOTHYROXINE; METHOTREXATE; METHYLPREDNISOLONE; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RETINOL; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

BONE MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; FRACTURE; GENETIC POLYMORPHISM; GERIATRIC CARE; HUMAN; KIDNEY DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; PATIENT MONITORING; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SEIZURE;

AGED; ANIMALS; ANTICONVULSANTS; CARDIOVASCULAR DISEASES; DEPRESSION; GASTROINTESTINAL AGENTS; HUMANS; KIDNEY DISEASES; NERVOUS SYSTEM DISEASES; OSTEOPOROSIS; PROTON PUMP INHIBITORS;

EID: 79960276332     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20269     Document Type: Review

References (117)

1. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older US women from NHANES III. J Bone Miner Res 1995; 10: 706-802.
2. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community dwelling older adults: a prospective study. J Am Geriatr Soc 1997; 45: 281-287. (Pubitemid 27114299)
3. Zimmerman S, Chandler JM, Hawkes W, et al. Effect of fracture on the health care use of nursing home residents. Arch Intern Med 2002; 162: 1502-1508. (Pubitemid 34747484)
4. Bishop CE, Gilden D, Blom J, et al. Medicare spending for injured elders: are there opportunities for savings? Health Aff (Millwood) 2002; 21: 215-223.
5. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-475. (Pubitemid 46797130)
6. Haentjens P, Magaziner J, Colõn-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380-390.
7. Loza E, Jover JA, Rodriguez L, et al. Multimorbidity: prevalence, effect on quality of life and daily functioning, and variation of this effect when one condition is a rheumatic disease. Semin Arthritis Rheum 2009; 38: 312-319.
8. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc 2009; 57: 225-230.
9. Uijen AA, van de Lisdonk EH,. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008; 14 (suppl 1): 28-32.
10. Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999; 9: 151-157. (Pubitemid 29219077)
11. Tuominen OM, Ylitalo-Heikkala R, Vehmas TI, et al. Effects of bisphosphonates on prostaglandin E2 and thromboxane B2 production in human whole blood and monocytes stimulated by lipopolysaccharide and A23187. Methods Find Exp Clin Pharmacol 2006; 28: 361-367. (Pubitemid 44221241)
12. Beloosesky Y, Hendel D, Weiss A, et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol A Biol Sci Med Sci 2007; 62: 420-426. (Pubitemid 47065711)
13. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of pro-inflammatory cytokines by peripheral blood gamma delta T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005; 139: 101-111. (Pubitemid 40066134)
14. Tsangari H, Findlay DM, Kuliwaba JS, et al. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone 2004; 35: 334-342. (Pubitemid 38789182)
15. Wimalawansa SJ,. Nitric oxide and bone. Ann N Y Acad Sci 2010; 1192: 391-403.
16. Albrand G, Munoz F, Sornay-Rendu E, et al. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 2003; 32: 78-85. (Pubitemid 36173815)
17. Sornay-Rendu E, Garnero P, Munoz F, et al. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 2003; 33: 159-166. (Pubitemid 36952697)
18. Nieves JW,. Nutritional therapies (including fosteum). Curr Osteoporos Rep 2009; 7: 5-11.
19. Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int 2003; 14: 677-682. (Pubitemid 41490353)
20. Resnick B, Orwig D, Yu-Yahiro J, et al. Testing the effectiveness of the exercise plus program in older women post-hip fracture. Ann Behav Med 2007; 34: 67-76. (Pubitemid 47481226)
21. Kaji H, Yamauchi M, Yamaguchi T, et al. Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metab 2010; 95: 4635-4642.
22. Kansal S, Fried L,. Bone disease in elderly individuals with CKD. Adv Chronic Kidney Dis 2010; 17: e41-e51.
23. Book C, Karlsson M, Akesson K, et al. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol 2008; 37: 248-254. (Pubitemid 351962323)
24. Coulson KA, Reed G, Gilliam BE, et al. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol 2009; 15: 155-160.
25. Lee RH, Lyles KW, Colõn-Emeric C,. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010; 8: 34-46.
26. O'Connell MB, Borgelt LM, Bowles SK, et al. Drug-induced osteoporosis in the older adult. Aging Health 2010; 10: 501-518.
27. Farhat GN, Newman AB, Sutton-Tyrrell K, et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int 2007; 18: 999-1008. (Pubitemid 46889559)
28. Tankõ, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women [published correction appears in J Bone Miner Res 2006;21:352]. J Bone Miner Res 2005; 20: 1912-1920. (Pubitemid 41532776)
29. Kado DM, Browner WS, Blackwell T, et al. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 2000; 15: 1974-1980.
30. Frost RJ, Sonne C, Wehr U, et al. Effects of calcium supplementation on bone loss and fractures in congestive heart failure. Eur J Endocrinol 2007; 156: 309-314. (Pubitemid 46554498)
31. van Diepen S, Majumdar SR, Bakal JA, et al. Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation 2008; 118: 1946-1952.
32. Laudisio A, Marzetti E, Antonica L, et al. Association of left ventricular function with bone mineral density in older women: a population-based study. Calcif Tissue Int 2008; 82: 27-33.
33. Mussolino ME, Armenian HK,. Low bone mineral density, coronary heart disease, and stroke mortality in men and women: the Third National Health and Nutrition Examination Survey. Ann Epidemiol 2007; 17: 841-846. (Pubitemid 47588957)
34. Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001; 357: 509-512. (Pubitemid 32173587)
35. Abedin M, Tintut Y, Demer LL,. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-1170. (Pubitemid 38880003)
36. Hofbauer LC, Brueck CC, Shanahan CM, et al. Vascular calcification and osteoporosis-from clinical observation towards molecular understanding. Osteoporos Int 2007; 18: 251-259. (Pubitemid 46233170)
37. Elshorbagy AK, Gjesdal CG, Nurk E, et al. Cysteine, homocysteine and bone mineral density: a role for body composition? Bone 2009; 44: 954-958.
38. Elshorbagy AK, Nurk E, Gjesdal CG, et al. Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism? Am J Clin Nutr 2008; 88: 738-746.
39. Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial [published correction arratum appears in JAMA 2006;296:396]. JAMA 2005; 293: 1082-1088. (Pubitemid 40300282)
40. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349. (Pubitemid 351930842)
41. Rejnmark L, Vestergaard P, Mosekilde L,. Fracture risk in patients treated with loop diuretics. J Intern Med 2006; 259: 117-124.
42. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341: c3691.
43. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164: 146-152. (Pubitemid 38140400)
44. Toh S, Hernández-Díaz S,. Statins and fracture risk: a systematic review. Pharmacoepidemiol Drug Saf 2007; 16: 627-640. (Pubitemid 47039529)
45. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 2004; 52: 1479-1486. (Pubitemid 39209595)
46. Fink HA, Kuskowski MA, Taylor BC, et al. Association of Parkinson's disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 2008; 19: 1277-1282.
47. Schneider JL, Fink HA, Ewing SK, et al. The association of Parkinson's disease with bone mineral density and fracture in older women. Osteoporos Int 2008; 19: 1093-1097.
48. Lui LY, Stone K, Cauley JA, et al. Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures. J Am Geriatr Soc 2003; 51: 38-43. (Pubitemid 36119932)
49. Yaffe K, Browner W, Cauley J, et al. Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc 1999; 47: 1176-1182. (Pubitemid 29473288)
50. Lazoura O, Groumas N, Antoniadou E, et al. Bone mineral density alterations in upper and lower extremities 12 months after stroke measured by peripheral quantitative computed tomography and DXA. J Clin Densitom 2008; 11: 511-517.
51. Lazoura O, Papadaki PJ, Antoniadou E, et al. Skelet al and body composition changes in hemiplegic patients. J Clin Densitom 2010; 13: 175-180.
52. Pouwels S, Lalmohamed A, Leufkens B, et al. Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke 2009; 40: 3281-3285.
53. Abou-Raya S, Helmii M, Abou-Raya A,. Bone and mineral metabolism in older adults with Parkinson's disease. Age Ageing 2009; 38: 675-680.
54. Ensrud KE, Walczak TS, Blackwell TL, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008; 71: 723-730.
55. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke [see comment Arch Intern Med 2007;167:513-514; author reply 514-515]. Arch Int Med 2005; 165: 1743-1748. (Pubitemid 41138962)
56. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women [see comment Neurology 2005;65:1513-1514]. Neurology 2005; 64: 811-816. (Pubitemid 40316317)
57. Ishani A, Paudel M, Taylor BC, et al. Osteoporotic Fractures in Men (MrOS) Study Group. Renal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Osteoporos Int 2008; 19: 1549-1556.
58. Kinsella S, Chavrimootoo S, Molloy MG, et al. Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis. Nephron Clin Pract 2010; 116: c256-c262.
59. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993; 43: 436-442. (Pubitemid 23162839)
60. Bailie GR, Massry SG,. National Kidney Foundation. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview. Pharmacotherapy 2005; 25: 1687-1707. (Pubitemid 41790092)
61. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 2007; 22: 503-508. (Pubitemid 47457426)
62. Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [published correction appears in N Engl J Med 2009;361:1914]. N Engl J Med 2009; 361: 756-765.
63. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geritr Soc 2000; 48: 721-725. (Pubitemid 30457407)
64. Stolee P, Poss J, Cook RJ, et al. Risk factors for hip fracture in older home care clients. J Gerontol A Biol Sci Med Sci 2009; 64: 403-410.
65. Magaziner J, Wehren L, Hawkes WG, et al. Women with hip fracture have a greater rate of decline in bone mineral density than expected: another significant consequence of a common geriatric problem. Osteoporos Int 2006; 17: 971-977. (Pubitemid 43864850)
66. Compston J,. (2010) Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010; 6: 82-88.
67. Vestergaard P,. Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy. Curr Drug Saf 2008; 3: 168-172.
68. Pack AM,. Implications of hormonal and neuroendocrine changes associated with seizures and antiepileptic drugs: a clinical perspective. Epilepsia 2010; 51 (suppl 3): 150-153.
69. Pack AM, Walczak TS,. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol 2008; 83: 305-328.
70. Poh CH, Navarro-Rodriguez T, Fass R,. Review: treatment of gastroesophageal reflux disease in the elderly. Am J Med 2010; 123: 496-501.
71. Yang YX,. Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 2008; 3: 204-209.
72. 45calcium carbonate absorption from an empty stomach: a randomized, double-blind, placebo-controlled, crossover clinical trial. Am J Med 2005; 118: 778-781. (Pubitemid 40897665)
73. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-259.
74. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 13-19.
75. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953. (Pubitemid 46021498)
76. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93-101.
77. Lenze EJ, Munin MC, Skidmore ER, et al. Onset of depression in elderly persons after hip fracture: implications for prevention and early intervention of late-life depression. J Am Geriatr Soc 2007; 55: 81-86. (Pubitemid 46046232)
78. Bruggemann L, Nixon RD, Cavenett T,. Predicting acute anxiety and depression following hip fracture. J Behav Med 2007; 30: 97-105. (Pubitemid 46426939)
79. Whitson HE, Sanders L, Pieper CF, et al. Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clin Exp Res 2008; 20: 585-592.
80. Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163: 949-957. (Pubitemid 36519740)
81. Diem SJ, Blackwell TL, Stone KL, et al. Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriatr Soc 2007; 55: 824-831. (Pubitemid 47011051)
82. Spangler L, Scholes D, Brunner RL, et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 2008; 23: 567-574.
83. Whooley MA, Kip KE, Cauley JA, et al. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 484-490.
84. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. J Am Geriatr Soc 2001; 49: 664-672.
85. Fredman L, Hawkes WG, Black S, et al. Elderly patients with hip fracture with positive affect have better functional recovery over 2 years. J Am Geriatr Soc 2006; 54: 1074-1081. (Pubitemid 43992544)
86. Lenze EJ, Munin MC, Dew MA, et al. Apathy after hip fracture: a potential target for intervention to improve functional outcomes. J Neuropsychiatry Clin Neurosci 2009; 21: 271-278.
87. Lenze EJ, Skidmore ER, Dew MA, et al. Does depression, apathy or cognitive impairment reduce the benefit of inpatient rehabilitation facilities for elderly hip fracture patients? Gen Hosp Psychiatry 2007; 29: 141-146. (Pubitemid 46335826)
88. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167: 1240-1245. (Pubitemid 46998494)
89. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167: 1246-1251. (Pubitemid 46998495)
90. Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005; 118: 1414.
91. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167: 188-194. (Pubitemid 46148067)
92. Vestergaard P, Rejnmark L, Mosekilde L,. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008; 82: 92-101.
93. Westbroek I, van der Plas A, de Rooij KE, et al. Expression of serotonin receptors in bone. J Biol Chem 2001; 276: 28961-28968.
94. Warden SJ, Haney EM,. Skelet al effects of serotonin (5- hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J Musculoskelet Neuronal Interact 2008; 8: 121-132.
95. Warden SJ, Robling AG, Haney EM, et al. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skelet al effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 2010; 46: 4-12.
96. Gillespie LD, Gillespie WJ, Robertson MC, et al. Interventions for preventing falls in elderly people. Cochrane Database Syst Rev 2003; CD000340.
97. Boult C, Boult LB, Morishita L, et al. A randomized clinical trial of outpatient geriatric evaluation and management. J Am Geriatr Soc 2001; 49: 351-359. (Pubitemid 32390865)
98. Boult C, Green AF, Boult LB, et al. Successful models of comprehensive care for older adults with chronic conditions: evidence for the Institute of Medicine's "retooling for an aging America" report. J Am Geriatr Soc 2009; 57: 2328-2337.
99. Barbour KA, Blumenthal JA,. Exercise training and depression in older adults. Neurobiol Aging 2005; 26 (suppl 1): 119-123.
100. Barbour KA, Edenfield TM, Blumenthal JA,. Exercise as a treatment for depression and other psychiatric disorders: a review. J Cardiopulm Rehabil Prev 2007; 27: 359-367.
101. Chubak J, Ulrich CM, Tworoger SS, et al. Effect of exercise on bone mineral density and lean mass in postmenopausal women. Med Sci Sports Exerc 2006; 38: 1236-1244. (Pubitemid 44036694)
102. Crepaldi G, Maggi S,. Epidemiologic link between osteoporosis and cardiovascular disease. J Endocrinol Invest 2009; 32 (4 suppl): 2-5.
103. Levels of evidence in AFP. Accessed May 3, 2011.
104. Markopoulos C, Tzoracoleftherakis E, Polychronis A, et al. Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 2010; 12: R24.
105. Nogues X, Servitja S, Peña MJ, et al. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas 2010; 66: 291-297.
106. Mazzantini M, Di Munno O, Sinigaglia L, et al. Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study. Clin Exp Rheumatol 2007; 25: 709-715. (Pubitemid 350300960)
107. Norenberg DD,. Furosemide, hypertension, and osteoporosis. JAMA 1979; 241: 237-238. (Pubitemid 9228423)
108. Holzbeierlein JM, Castle EP, Thrasher JB,. Complications of androgen-deprivation therapy for prostate cancer. Clin Prostate Cancer 2003; 2: 147-152. (Pubitemid 38044661)
109. Miyaji Y, Saika T, Yamamoto Y, et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 2004; 64: 128-131. (Pubitemid 38887592)
110. Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2009; 68: 1898-1901.
111. Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95: 186-193.
112. Misra M, Papakostas GI, Klibanski A,. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607-1618.
113. Thacker H,. Glucocorticoid-induced osteoporosis. Cleve Clinic J Med 2010; 77: 843-844.
114. Berberoglu Z, Yazici AC, Demirag NG,. Effects of rosiglitazone on bone mineral density and remodelling parameters in postmenopausal diabetic women: a 2-year follow-up study. Clin Endocrinol 2010; 73: 305-312.
115. Lecka-Czernik B,. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Current Osteoporos Rep 2010; 8: 178-184.
116. Lefkou E, Khamashta M, Hampson G, et al. Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity? Lupus 2010; 19: 3-12.
117. Caire-Juvera G, Ritenbaugh C, Wactawski-Wende J, et al. Vitamin A and retinol intakes and the risk of fractures among participants of the Women's Health Initiative Observational Study. Am J Clin Nutr 2009; 89: 323-330.